Market Place
Sourcing Support
Ocuphire Pharma Announces Acquisition of Opus Genetics
22 Oct 2024 //
GLOBENEWSWIRE
Opus Genetics` OPGx-LCA5 Gets FDA Rare Pediatric Disease Designation
20 Aug 2024 //
GLOBENEWSWIRE
Opus Announces $1.7 Million Funding to Support Two Preclinical Programs
13 Jun 2024 //
GLOBENEWSWIRE
Opus Announces Comp of Dosing of Ph 1/2 of OPGx-LCA5 for Retinal Disease LCA5
26 Mar 2024 //
GLOBENEWSWIRE
Data on Potential of Opus AAV-based Gene Therapy to be Presented
03 Nov 2023 //
GLOBENEWSWIRE
Opus Genetics Announces First Patient Dosed in Phase 1/2 Trial of OPGx-LCA5
07 Sep 2023 //
GLOBENEWSWIRE
Opus Genetics acquires two gene therapy candidates from Iveric Bio
29 Dec 2022 //
HEALIO
Opus Genetics Receives FDA Clearance of IND Application for OPGx-001
01 Dec 2022 //
GLOBENEWSWIRE
Opus Genetics Sponsors Uni-Rare Natural History Study for People with IRD
14 Nov 2022 //
BIOSPACE
Opus Genetics Expands Board Directors with Appointment of Global Ophthalmology
27 Sep 2022 //
GLOBENEWSWIRE
Opus Genetics Leadership to Present at 3rd Annual Gene Therapy for Ophthalmic
12 Sep 2022 //
GLOBENEWSWIRE
Opus Genetics Hosts Inaugural Patient Advocacy Outreach Webinar
01 Sep 2022 //
GLOBENEWSWIRE
Opus Genetics to Present at OIS Retina Innovation Summit 2022
11 Jul 2022 //
GLOBENEWSWIRE
Opus Genetics Appoints Ben Yerxa, Ph.D., as Permanent Chief Executive Officer
21 Jun 2022 //
GLOBENEWSWIRE
Opus Genetics Appoints Jennifer Hunt Chief Development Officer
11 May 2022 //
GLOBENEWSWIRE
Opus Genetics Announces Data on AAV-based Gene Therapies
04 May 2022 //
GLOBENEWSWIRE
New Data on Opus AAV-based Gene Therapies for Rare Inherited Retinal Diseases
28 Apr 2022 //
GLOBENEWSWIRE
Opus Enters Strategic Collaboration with Resilience for AAV-based Gene Therapy
11 Apr 2022 //
GLOBENEWSWIRE
Opus Partners with Massachusetts Eye and Ear and Harvard Medical School
11 Nov 2021 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.